1. Volume 125, Issue 1, Pages 107-116 (July 2003)
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1  
Chris Westland, William Delaney, Huiling Yang, Shan-shan Chen, Patrick Marcellin, Stephanos Hadziyannis, Robert Gish, John Fry, Carol Brosgart, Craig Gibbs, Michael Miller, Shelly Xiong 
Gastroenterology 
Volume 125, Issue 1, Pages (July 2003)
DOI: /S (03)

2. Figure 1
Phylogenetic tree depicting the analysis of baseline HBV sequences from 171 patients treated with adefovir dipivoxil 10 mg from study GS along with 70 Genbank HBV sequences of known genotype. Genbank HBV sequences are labeled (A-G) to indicate genotype; patient sequences are unlabeled. A chimpanzee hepatitis B virus sequence was used as an outgroup during the analysis. Scale bar indicates the number of substitutions per site.
Gastroenterology  , DOI: ( /S (03) )

3. Figure 2
Distribution of HBV genotypes in patients enrolled in phase III trials of adefovir dipivoxil. HBV genotypes were determined for 694 chronic hepatitis B patients using the methods described in Figure 1. (A) A total of 510 patients had HBeAg+ chronic hepatitis B and the distribution of HBV genotypes in this population is indicated as a percentage of total HBeAg+ patients. (B) The remaining patients (n = 184) had HBeAg− chronic hepatitis B and the distribution of HBV genotypes in this population is indicated as a percentage of total HBeAg− patients.
Gastroenterology  , DOI: ( /S (03) )

4. Figure 3
Geographic distribution of HBV genotypes. The HBV genotypes of patients enrolling at geographically distinct study sites are indicated as a percentage of the total patient population in each region. (A) Asian/Oceanic study sites, (B) North American study sites, (C) Mediterranean study sites, and (D) European study sites. Countries enrolling patients in each geographic region are listed in the Materials and Methods section.
Gastroenterology  , DOI: ( /S (03) )

5. Figure 4
Racial distribution of HBV genotypes. The HBV genotypes of patients of different races are indicated as percentages of the total patient population of each race. (A) HBV genotypes in Asian patients, (B) HBV genotypes in Caucasian patients, and (C) HBV genotypes in African-American patients.
Gastroenterology  , DOI: ( /S (03) )

6. Figure 5
Baseline levels of serum HBV DNA in chronic hepatitis B patients stratified by genotype. (A) A total of 510 HBeAg+ patients and (B) 184 HBeAg− patients that participated in phase III trials of adefovir dipivoxil. In both panels, each point represents the baseline serum HBV DNA (log10 copies/mL) measurement in a single patient; solid bars represent the mean level of serum HBV DNA for the indicated patient group. The mean baseline serum HBV DNA (log10 copies/mL) in HBeAg+ patients was 8.44 for genotype A patients, 8.25 for B, 7.83 for C, 8.47 for D, 7.11 for E, 7.66 for F, and 9.49 for G. The mean baseline serum HBV DNA (log10 copies/mL) in HBeAg− patients was 6.44 for genotype A, 6.51 for B, 6.52 for C, 7.16 for D, 7.22 for E, and 6.83 for F. Serum HBV-DNA levels were significantly different between genotypes as determined by overall comparisons with the Kruskal-Wallis test (< for both HBeAg+ and HBeAg− populations, refer to the text for significant pairwise differences between genotypes).
Gastroenterology  , DOI: ( /S (03) )